Trading indicator
Fibonacci ExtensionsTrade setup
| Position | Order | Entry | Exit | Stop Loss | Risk | Return | Expectancy |
| Long | 10 | 4.5 | 20% | 25% | 1.6% | -0.8% | -3.4% |
|---|---|---|---|---|---|---|---|
| Short | 5 | 4.2 | 40% | 67% | 1.9% | -3.2% | -5.9% |
Backtest results
| Position | Trades | Duration | Win rate | Win/loss | Avg win | Avg loss | Return |
| Long | 10 | 4.5 | 20% | 25% | 1.6% | -0.8% | -3.4% |
|---|---|---|---|---|---|---|---|
| Short | 5 | 4.2 | 40% | 67% | 1.9% | -3.2% | -5.9% |
Company
Indicator
| Code | Company | Date | Close | Change | Indicator | Value | Signal |
|---|
Trading Performance
Fibonacci Extensions
Score
-0.65
| Position | Trades | Duration | Win Rate | Win/Loss | Avg Win | Avg Loss | Return |
|---|---|---|---|---|---|---|---|
| LONG | 9 | 37.8 | 0.44% | 0.80% | 8.2% | -8.6% | -10.1% |
| SHORT | 9 | 39.0 | 0.33% | 0.50% | 9.2% | -10.7% | -36.5% |
Summary
Technical Analysis
Mesoblast (MSB.AX)
Indicator:
FIBONACCI EXTENSION
Signal Strength: MEDIUM
Recommendation:
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading position.
Mesoblast (ASX:MSB) : The current Fibonacci Extension levels are:
(23.61%) $1.92
(38.2%) $1.89
(50%) $1.86
(61.8%) $1.83
The current support levels are:
(78.6%) $1.79
(100%) $1.75
(138.2%) $1.66
(161.8%) $1.6
(261.8%) $1.37
(423.61%) $1
Fibonacci extensions are used in Fibonacci retracement to predict spaces of resistance and support in the market. These extensions involve all levels drawn past the basic 100% level they are frequently used by traders to determine areas that will bring in profits.
Calculation: Fibonacci Extensions:
1) Uptrend: D = B — (A — B) x N%;
2) Downtrend: D = B + (B — A) x N %;
3) Fibonacci Levels:
61.8%
100%
138.2%
161.8%
261.8%
423.6%;
PROFILE: Mesoblast (MSB.AX)
Stock Exchange: ASX
Company: Mesoblast
Ticker Codes: | MSB.AX | ASX:MSB |
Mesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions. The company's products under the Phase III clinical trials include MPC-150-IM for chronic and end-stage heart failure; MPC-06-ID for chronic low back pain; and MSC-100-IV for acute graft versus host disease in children. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, and diabetic kidney diseases and type 2 diabetes. The company has a collaboration agreement with JCR Pharmaceuticals Co., Ltd. It has operations in the United States, Australia, Singapore, and Switzerland. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.
Top 10:
Fibonacci Extensions
| Company | Close | Change(%) | Volume | Value | Signal |
|---|---|---|---|---|---|
| OCL Objective Corporation | 6.49 | 10 | 35,078 | 3.21 | BULLISH |
| MCY Mighty River Power | 5 | 7.1 | 7,917 | 1.21 | BULLISH |
| RCT Reef Casino | 2.62 | 6.9 | 38,587 | 0.53 | BULLISH |
| LNG Liquefied Natural Gas | 0.21 | 5.1 | 2,729,105 | 0.21 | BULLISH |
| MEZ Meridian Energy | 4.9 | 4.4 | 46,590 | 1.48 | BULLISH |
| CAR Carsales | 16.74 | 4 | 912,376 | 2.27 | BULLISH |
| BPT Beach Petroleum | 2.49 | 3.8 | 6,575,446 | 0.37 | BULLISH |
| PGC Paragon Care | 0.45 | 3.5 | 206,495 | 0.08 | BULLISH |
| EMH European Metals Holdings | 0.31 | 3.3 | 53,950 | 0.11 | BULLISH |
| IGL International Goldfields | 2.34 | 3.1 | 734,472 | 0.58 | BULLISH |